drugset / Trial / NCT00834587
5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
RandomizedCrossoverOpen-label
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under non-fasting conditions.
Timeline
- Start
- 2004-06
- Primary completion
- 2004-06
- Completion
- 2004-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glipizide | Small molecule | 5 mg | Oral |
| Subject | Metformin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.